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BACKGROUND. Matrix metalloprotease 9 (MMP-9) is associated with inflammation and
lung remodeling in chronic obstructive pulmonary disease (COPD). We hypothesized that
elevated circulating MMP-9 represents a potentially novel biomarker that identifies a subset
of individuals with COPD with an inflammatory phenotype who are at increased risk for
acute exacerbation (AECOPD).
METHODS. We analyzed Subpopulations and Intermediate Outcome Measures in COPD
Study (SPIROMICS) and Genetic Epidemiology of COPD (COPDGene) cohorts for which
baseline and prospective data were available. Elevated MMP-9 was defined based on
>95th percentile plasma values from control (non-COPD) sample in SPIROMICS. COPD
subjects were classified as having elevated or nonelevated MMP-9. Logistic, Poisson, and
Kaplan-Meier analyses were used to identify associations with prospective AECOPD in
both cohorts.
RESULTS. Elevated MMP-9 was present in 95/1,053 (9%) of SPIROMICS and 41/140
(29%) of COPDGene participants with COPD. COPD subjects with elevated MMP-9 had a
13%–16% increased absolute risk for AECOPD and a higher median (interquartile range;
IQR) annual AECOPD rate (0.33 [0–0.74] versus 0 [0–0.80] events/year and 0.9 [0.5–2]
versus 0.5 [0–1.4] events/year for SPIROMICS and COPDGene, respectively). In adjusted
models within each cohort, elevated MMP-9 was associated with increased […]
Clinical Medicine Pulmonology
Find the latest version:
http://jci.me/123614/pdf
1insight.jci.org   https://doi.org/10.1172/jci.insight.123614
C L I N I C A L  M E D I C I N E
Conflict of interest: JMW has received 
grant support and consulting fees from 
GSK, AZ, Gilead, Bayer, Quintiles, Mylan, 
and Mereo BioPharma. MTD has received 
grants from; Consulting fees from 
AstraZeneca, BI, GSK, PneummRx/BTG, 
and Quark; and contracted clinical trial 
support from AstraZeneca, BI, Boston 
Scientific, GSK, Novartis PneumRx/
BTG, Pulmonx, and Yungjin. JLC has 
received grants from MedImmune Corp. 
Ltd. IB has received grant support and 
consulting fees from AZ, Grifols, CSL 
Behring, and Amgen. EKS has received 
honoraria from Novartis for Continuing 
Medical Education Seminars and grant 
and travel support from GSK. PJC has 
received grant support and consulting 
fees from GSK. AG has received grant 
support from the and consulting fees 
from Gilead Sciences, Grifols Inc., and 
Celtaxsys Inc.
License: Copyright 2018, American 
Society for Clinical Investigation.
Submitted: July 16, 2018 
Accepted: October 4, 2018 
Published: November 15, 2018
Reference information: 
JCI Insight. 2018;3(22):e123614. 
https://doi.org/10.1172/jci.
insight.123614.
Elevated circulating MMP-9 is linked 
to increased COPD exacerbation risk in 
SPIROMICS and COPDGene
J. Michael Wells,1,2,3 Margaret M. Parker,4 Robert A. Oster,5 Russ P. Bowler,6 Mark T. Dransfield,1,2,3 
Surya P. Bhatt,1,2 Michael H. Cho,4 Victor Kim,7 Jeffrey L. Curtis,8,9 Fernando J. Martinez,10  
Robert Paine III,11,12 Wanda O’Neal,13 Wassim W. Labaki,8 Robert J. Kaner,10 Igor Barjaktarevic,14 
MeiLan K. Han,8 Edwin K. Silverman,4 James D. Crapo,6 R. Graham Barr,15 Prescott Woodruff,16  
Peter J. Castaldi,4 Amit Gaggar,1,2,3 and the SPIROMICS and COPDGene Investigators17
1Division of Pulmonary and Critical Care, University of Alabama at Birmingham, Birmingham, Alabama, USA. 2UAB Lung 
Health Center, Birmingham, Alabama, USA. 3Birmingham VA Medical Center, Birmingham, Alabama, USA. 4Channing 
Division of Network Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA. 5Division of Preventive 
Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA. 6Division of Pulmonary, Critical Care 
Medicine, National Jewish Health, Denver, Colorado, USA. 7Thoracic Medicine and Surgery, Lewis Katz School of Medicine, 
Temple University, Philadelphia, Pennsylvania, USA. 8Division of Pulmonary and Critical Care Medicine, University 
of Michigan, Ann Arbor, Michigan, USA. 9Medical Service, VA Ann Arbor Healthcare System, Ann Arbor, Michigan, 
USA. 10Departments of Medicine and Genetic Medicine, Weill Cornell Medicine, New York, New York, USA. 11Division of 
Respiratory, Critical Care, and Occupational Pulmonary Medicine, University of Utah, Salt Lake City, Utah, USA.  
12Medical Service, Salt Lake City VA Medical Center, Salt Lake City, Utah, USA. 13Marsico Lung Institute/Cystic Fibrosis 
Research Center, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.  
14Division of Pulmonary and Critical Care Medicine, UCLA, Los Angeles, California, USA. 15Department of Medicine, 
Columbia University Medical Center, New York, New York, USA. 16Division of Pulmonary and Critical Care Medicine, 
UCSF, School of Medicine, San Francisco, California, USA. 17The SPIROMICS and COPDGene groups are detailed in the 
Supplemental Acknowledgments.
BACKGROUND. Matrix metalloprotease 9 (MMP-9) is associated with inflammation and lung 
remodeling in chronic obstructive pulmonary disease (COPD). We hypothesized that elevated 
circulating MMP-9 represents a potentially novel biomarker that identifies a subset of individuals 
with COPD with an inflammatory phenotype who are at increased risk for acute exacerbation 
(AECOPD).
METHODS. We analyzed Subpopulations and Intermediate Outcome Measures in COPD Study 
(SPIROMICS) and Genetic Epidemiology of COPD (COPDGene) cohorts for which baseline and 
prospective data were available. Elevated MMP-9 was defined based on >95th percentile plasma 
values from control (non-COPD) sample in SPIROMICS. COPD subjects were classified as having 
elevated or nonelevated MMP-9. Logistic, Poisson, and Kaplan-Meier analyses were used to identify 
associations with prospective AECOPD in both cohorts.
RESULTS. Elevated MMP-9 was present in 95/1,053 (9%) of SPIROMICS and 41/140 (29%) of 
COPDGene participants with COPD. COPD subjects with elevated MMP-9 had a 13%–16% increased 
absolute risk for AECOPD and a higher median (interquartile range; IQR) annual AECOPD rate 
(0.33 [0–0.74] versus 0 [0–0.80] events/year and 0.9 [0.5–2] versus 0.5 [0–1.4] events/year for 
SPIROMICS and COPDGene, respectively). In adjusted models within each cohort, elevated MMP-9 
was associated with increased odds (odds ratio [OR], 1.71; 95%CI, 1.00–2.90; and OR, 3.03; 95%CI, 
1.02–9.01), frequency (incidence rate ratio [IRR], 1.45; 95%CI, 1.23–1.7; and IRR, 1.24; 95%CI, 
1.03–1.49), and shorter time-to-first AECOPD (21.7 versus 31.7 months and 14 versus 21 months) in 
SPIROMICS and COPDGene, respectively.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder characterized by progressive 
airflow limitation leading to functional impairment. Acute exacerbations of  COPD (AECOPD) are critical 
events in the natural history of  COPD, affecting quality of  life, trajectory of  lung function loss, and mortal-
ity (1–3). However, the biologic pathways conveying increased risk for these events are poorly understood, 
and a biomarker of  risk remains elusive. Recent studies analyzing large panels of  biomarkers as predictors 
for AECOPD risk have found various markers were associated with AECOPD within individual cohorts, 
but replication across COPD populations is poor (4). The identification of  a reproducible biomarker for 
AECOPD would provide key prognostic value and, if  causally linked to pathogenesis, could present a new 
therapeutic target for AECOPD prevention or treatment.
Among the many inflammatory pathways and mediators implicated in COPD development, proteases 
are particularly relevant to the pathophysiology of  the disease. Inflammation alters protease/antiprotease bal-
ance, leading to progressive airway destruction and remodeling. The matrix metalloproteases (MMPs) have 
been connected to the development of  emphysema through direct and indirect mechanisms (5–8). MMP-9 
uniquely mediates pulmonary inflammation through extracellular matrix degradation, neutrophil chemotax-
is, and augmentation of  inflammation (7, 9) — key features of  AECOPD. To date, no clinical study has eval-
uated the impact of  elevated MMP-9 on important events including risk of  COPD exacerbation.
We sought to understand if  there were associations between MMP-9 and AECOPD, thus establish-
ing its relevance as a COPD biomarker. As opposed to prior work investigating mean MMP-9 values, we 
used the approach of  defining elevated MMP-9 based on >95th percentile values derived from non-COPD 
Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) subjects and then 
applied this threshold in predicting risk for AECOPD, a well-validated approach to defining biomarkers in 
many disorders (10–12). We hypothesized that elevated systemic MMP-9 identifies a subset of  individuals 
with COPD with an inflammatory phenotype who are at increased risk for AECOPD.
Results
Ascertainment of elevated MMP-9. Flow diagrams for SPIROMICS and Genetic Epidemiology of  COPD 
(COPDGene) are shown in Figure 1. In SPIROMICS, there were 624 individuals in strata 1 and 2 (non-
CONCLUSIONS. Elevated MMP-9 was independently associated with AECOPD risk in 2 well-
characterized COPD cohorts. These findings provide evidence for MMP-9 as a prognostic 
biomarker and potential therapeutic target in COPD.
TRIAL REGISTRATION. ClinicalTrials.gov: NCT01969344 (SPIROMICS) and NCT00608764 
(COPDGene).
FUNDING. This work was funded by K08 HL123940 to JMW; R01HL124233 to PJC; Merit Review 
I01 CX000911 to JLC; R01 (R01HL102371, R01HL126596) and VA Merit (I01BX001756) to AG. 
SPIROMICS (Subpopulations and Intermediate Outcomes in COPD Study) is funded by contracts 
from the NHLBI (HHSN268200900013C, HHSN268200900014C,HHSN268200900015C 
HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, 
and HHSN268200900020C) and a grant from the NIH/NHLBI (U01 HL137880), and supplemented 
by contributions made through the Foundation for the NIH and the COPD Foundation 
from AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim 
Pharmaceuticals Inc.; Chiesi Farmaceutici; Forest Research Institute Inc.; GlaxoSmithKline; 
Grifols Therapeutics Inc.; Ikaria Inc.; Novartis Pharmaceuticals Corporation; Nycomed GmbH; 
ProterixBio; Regeneron Pharmaceuticals Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; 
and Theravance Biopharma and Mylan. COPDGene is funded by the NHLBI (R01 HL089897 and 
R01 HL089856) and by the COPD Foundation through contributions made to an Industry Advisory 
Board composed of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, 
Siemens, and Sunovion.
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COPD controls) who had plasma MMP-9 measured. These non-COPD study participants were 60 ± 10 
years old, 68% White, and 46% male (Table 1). Plasma MMP-9 was 2.14 ± 0.33 ng/ml (log-transformed) 
for non-COPD controls, and the 95th percentile value of  2.67 ng/ml log-transformed was used to indi-
cate elevated MMP-9. The distributions of  MMP-9 in the COPD cohorts are shown in Figure 2. In SPI-
ROMICS, the 1,053 individuals with COPD and with plasma MMP-9 values were 66 ± 8 years old, 83% 
White, 59% male, and 33% current smokers, and they had a mean post-bronchodilator forced expiratory 
volume in 1 second (FEV1) of  62% ± 23% predicted (Table 1). In the SPIROMICS COPD cohort, the aver-
age plasma level of  MMP-9 was 2.21 ± 0.33 ng/ml log-transformed, and 95 individuals (9%) had elevated 
MMP-9 using the 2.67 ng/ml log-transformed threshold. Among the participants in SPIROMICS with 
COPD who were included in the primary analysis, 290 had a second plasma MMP-9 measurement per-
formed after 1 year of  follow-up, and the variation of  MMP-9 over time is shown in Supplemental Figure 1 
(supplemental material available online with this article; https://doi.org/10.1172/jci.insight.123614DS1). 
The coefficient of  variation of  logMMP-9 was 14.7% for Visit 1 and 14.8% for Visit 2.
Within COPDGene, 140 individuals had COPD and plasma MMP-9 measurements available. Partic-
ipants in this validation cohort were 64 ± 9 years old, 100% White, 46% male, and 19% current smokers 
and had a mean postbronchodilator FEV1 of  42% ± 17% predicted (Table 1). The average plasma MMP-9 
was 2.54 ± 0.26 ng/ml log-transformed, with 41 (29%) classified as elevated MMP-9. The distributions 
of  MMP-9 values across Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages for both 
cohorts are shown in Figure 3.
Characteristics of  individuals with COPD and elevated MMP-9. Compared with participants with non-
elevated MMP-9, SPIROMICS participants with elevated MMP-9 were more often current smokers 
(51% vs. 31%, P < 0.001) and had a higher proportion of  chronic bronchitis (39% vs. 26%, P = 0.012), 
higher WBC count, higher neutrophil percent, and lower eosinophil percent (Table 2). In COPD-
Gene, participants with elevated MMP-9 were younger, more likely current smokers (32% vs. 13%, 
P < 0.001), and had higher WBC count and neutrophil percent as compared with the nonelevated 
Figure 1. Flow diagrams for the participants in the study. (A) SPIROMICS and (B) COPDGene. All allocated subjects in 
both cohorts were included in analysis. COPD, chronic obstructive pulmonary disease; MMP, matrix metalloprotease.
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MMP-9 group (Table 3). However, in both cohorts, we found no significant differences between indi-
viduals with elevated MMP-9 and those with normal MMP-9 values in race (in SPIROMICS only), 
sex, BMI, lung function, pack-year history of  smoking, comorbid conditions, or proportion of  who 
had a previous AECOPD within the 12 months before baseline evaluation. While we observed ~12% 
higher tissue inhibitor of  metalloproteinase 1 (TIMP-1) levels in the elevated MMP-9 group compared 
with the nonelevated MMP-9 group in SPIROMICS (Table 2), there were no intergroup differences 
observed in COPDGene (Table 3).
Associations between elevated MMP-9 and prospective AECOPD in SPIROMICS. Participants with COPD 
in SPIROMICS were followed for a median of  34 months (IQR25–75 25–37). During this time, 527 (50.5%) 
developed at least 1 AECOPD (median 1; IQR25–75 0–2). Participants in the elevated MMP-9 group had 
a 16% higher absolute risk for having ≥1 AECOPD during follow-up compared with the group without 
elevated MMP-9 (65% vs. 49%, P = 0.003). In unadjusted logistic regression models, elevated MMP-9 was 
associated with prospective AECOPD (OR, 1.92; 95% CI, 1.23–2.99; P = 0.004), as were age, sex, lower 
FEV1 percent predicted, chronic bronchitis, WBC, and an AECOPD in the year before the baseline eval-
uation (Supplemental Table 1). Moreover, elevated MMP-9 was independently associated with AECOPD 
(OR, 1.71; 95% CI, 1.00–2.90; P = 0.049) in a logistic regression model adjusting for age, sex, race, FEV1 
percent predicted, current smoking, chronic bronchitis, WBC count, and previous AECOPD (Figure 4A 
and Supplemental Table 2). There was no significant interaction between elevated MMP-9 and WBC (P = 
0.81) or elevated MMP-9 and PMN counts (P = 0.78) for AECOPD. The area under the receiver operating 
curve was 0.74 (95% CI, 0.71–0.77; P < 0.001).
In SPIROMICS, the median [IQR25–75] annual AECOPD rate was higher in the elevated MMP-9 group 
compared with the nonelevated MMP-9 group (0.33 [0–0.74] events/year versus 0 [0–0.80] events/year, 
P = 0.013). In Poisson regression models adjusted for age, sex, FEV1 percent predicted, chronic bronchi-
tis, WBC count, and previous AECOPD, elevated MMP-9 was independently associated with increased 
AECOPD frequency (incidence rate ratio [IRR], 1.45; 95% CI, 1.23–1.71; P < 0.001) (Figure 4B and Sup-
plemental Table 3). In SPIROMICS, elevated MMP-9 was associated with a shorter median time-to-first 
AECOPD (21.7 vs. 31.7 months, P = 0.015) as shown in Figure 5A.
Associations between elevated MMP-9 and prospective AECOPD in COPDGene. We next aimed to rep-
licate our findings using data from COPDGene, in which participants were followed for 64 (IQR25–75 
45–73) months and 100 (74%) developed at least 1 AECOPD (median 3; IQR25–75 0–6). In this cohort, 
participants with elevated MMP-9 had a 13% higher absolute risk (83% vs. 70%, P = 0.103) for having 
Table 1. Baseline characteristics
SPIROMICS Non-COPD (n = 624) SPIROMICS COPD (n = 1053) COPDGene COPD (n = 140)
Age, years 60 ± 10 66 ± 8 64 ± 9
White 426 (68%) 875 (83%) 140 (100%)
Male 288 (46%) 616 (59%) 64 (46%)
BMI, kg/m2 28.8 ± 5.2 27.5 ± 5.2 27.7 ± 5.8
Post-BD FEV1, % predicted 98 ± 13 62 ± 23 42 ± 17
Post-BD FVC, % predicted 96 ± 13 89 ± 19 77 ± 21
FEV1/FVC 0.78 ± 0.05 0.52 ± 0.13 0.41 ± 0.13
Current smoker 228/616 (37%) 339/1034 (33%) 26 (19%)
Pack-years 33 ± 25 53 ± 24 54 ± 29
Chronic bronchitis 70/602 (12%) 269/988 (27%) 34 (24%)
WBC, 1 × 109 cell/ml 6.4 ± 1.9 7.2 ± 2.1 7.6 ± 2.2
Serum neutrophil, % 58 ± 10 62 ± 10 64 ± 10
Serum eosinophil, % 3 ± 2 3 ± 2 3 ± 2
Any AECOPD within previous 12 months 70 (11%)A 301 (29%) 76 (54%)
Log MMP-9 2.14 ± 0.33 2.21 ± 0.33 2.54 ± 0.26
TIMP-1, ng/ml 85.6 ± 28.8 89.5 ± 27.6 67.8 ± 13.6
Data expressed as mean ± SD or n (%). BD, bronchodilator; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; AECOPD, acute 
exacerbation of COPD; MMP-9, matrix metalloprotease 9. AAcute respiratory events.
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≥1 AECOPD during follow-up compared with the group without elevated MMP-9. Elevated MMP-9 
was independently associated with prospective AECOPD (OR, 3.03; 95% CI, 1.02–9.01; P = 0.046) in 
adjusted logistic regression models (Figure 4A and Supplemental Table 2). There was no significant 
interaction between elevated MMP-9 and WBC (P = 0.081) or elevated MMP-9 and PMN counts (P 
= 0.26) for AECOPD. In COPDGene, the median (IQR25–75) annualized AECOPD rate was higher in 
the elevated MMP-9 group compared with the nonelevated group (0.9 [0.5–2] events/year versus 0.5 
[0–1.4] events/year, P = 0.029). In Poisson models adjusted for age, sex, race, FEV1 percent predicted, 
current smoking, chronic bronchitis, WBC count, and previous AECOPD, MMP-9 elevation was asso-
ciated with increased AECOPD IRR (IRR, 1.24; 95% CI, 1.03–1.49; P = 0.024; Figure 4B and Sup-
plemental Table 3). Unadjusted Poisson models for both cohorts are reported in Supplemental Table 
4. Elevated MMP-9 was associated with a shorter median time-to-first AECOPD in COPDGene (14 
versus 21 months, P = 0.065), as shown in Figure 5B. There were no associations between TIMP-1 and 
AECOPD in either cohort (Supplemental Tables 1 and 4).
Discussion
Elevated plasma MMP-9 was associated with the risk of  prospective acute exacerbations in 2 well-char-
acterized COPD populations, even when adjusted for established clinical risk factors for exacerbations, 
including lung function; symptoms including chronic bronchitis; leukocyte counts; and previous exacerba-
Figure 2. Plasma MMP-9 distribution in the 2 cohorts. (A) The distribution of log-transformed MMP-9 values in 1,053 individuals with COPD in SPIROMICS. (B) 
The distribution of log-transformed MMP-9 values in 140 individuals with COPD in COPDGene. The red line corresponds to elevated MMP-9 (MMP-9 >2.67 ng/ml, 
log transformed; defined as the 95th percentile value in the non-COPD cohort). COPD, chronic obstructive pulmonary disease; MMP, matrix metalloprotease.
Figure 3. MMP-9 values across GOLD stages. MMP-9 (ng/ml log transformed) values were different across GOLD stage in (A) SPIROMICS (P = 0.023) but 
not in (B) COPDGene (P = 0.48) by 1-way ANOVA. In COPDGene, GOLD stages 1 and 2 were combined due to the presence of a single GOLD stage 1 partici-
pant. The values included within the box(es) represent the interquartile range, the horizontal line the median, and the whiskers the 95% CI; outliers are 
represented by circles. GOLD, Global initiative for Obstructive Lung Disease; MMP, matrix metalloproteinase.
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tions (13). These findings help advance our understanding of  the potential role for MMP-9 in the natural 
history of  COPD, providing insight about the stability of  MMP-9 measurement over time and measuring 
the prognostic significance of  elevated circulating MMP-9. A major strength of  our study was replicat-
ing the associations between MMP-9 elevation and AECOPD in 2 different clinical cohorts. Our findings 
address a key first step in establishing evidentiary criteria suggested by the Foundation for the NIH (FNIH) 
in qualifying MMP-9 elevation as a blood-based biomarker with clinical utility in COPD (14).
These results extend the few studies evaluating the association of MMP-9 in COPD populations by link-
ing systemic levels of the protease to a clinically meaningful prospective outcome. In contrast to our study, 
most of the published literature about MMP-9 focuses on sputum or bronchoalveolar lavage (BAL) MMP-9 
in COPD. These studies have shown associations between MMP-9 and lower lung function, metrics of small 
airways disease or emphysema on CT imaging (15, 16), and elevated MMP-9 levels during AECOPD (17–20). 
Although these studies have provided a rationale for the importance of MMP-9 in COPD, they have been limit-
ed by relatively small sample sizes and reliance on BAL or sputum measurements, samples that are impractical 
for deploying into routine clinical care. To our knowledge, the largest longitudinal study of plasma MMP-9 in 
non–α-1 anti-trypsin–related COPD included 101 participants (21). In that study, D’Armiento and colleagues 
did not show relationships with disease progression, but they did not assess exacerbation risk. In α-1 anti-trypsin 
deficiency, plasma MMP-9 is associated with greater exacerbation frequency (22), supporting our current find-
ings. Our study addressed gaps in our understanding of the prognostic importance of MMP-9 in COPD through 
analyzing 2 of the largest, well-characterized, prospective cohorts of COPD patients to date.
The use of  an empirically defined biomarker values has been used previously in COPD (23, 24). In 
the Evaluation of  COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) cohort, 
Agustí and colleagues described an endotype of  persistent systemic inflammation by measuring a panel 
of  6 nonspecific inflammatory biomarkers, including WBC, c-reactive protein (CRP), IL-6, IL-8, fibrino-
gen, and TNF-α (23). Participants with ≥2 elevated biomarkers compared with those with no biomarker 
elevations had higher rates of  AECOPD the year prior to enrollment, higher rates of  smoking, and more 
symptoms. In an analysis of  2 general population–based studies from Copenhagen, Thomsen et al. found 
associations between a panel of  inflammatory biomarkers (WBC, CRP, and fibrinogen) and exacerbation 
risk (24). The authors found that the risk of  AECOPD increased as the number of  elevated biomarkers 
increased in a dose-dependent manner, albeit the overall magnitude of  effects (5%, 12%, or 20% absolute 
difference for elevations in 1, 2, or 3 markers, respectively) were similar to our current observations with 
Table 2. Differences in characteristics between elevated and nonelevated MMP-9 in COPD in SPIROMICS
Nonelevated 
MMP-9 (n = 958)
Elevated MMP-9 (n = 95) Mean difference 
(95% CI)
P value
Age, years 66 ± 8 65 ± 8 1.5 (–0.2 to 3.2) 0.08
White 790 (83%) 85 (90%) 0.08
Male 562 (59%) 54 (57%) 0.73
BMI, kg/m2 27.5 ± 5.3 27.2 ± 5.0 0.3 (–0.8 to 1.4) 0.60
Post-BD FEV1, % predicted 62 ± 24 61 ± 20 2 (–3 to 7) 0.50
Post-BD FVC, % predicted 89 ± 20 90 ± 17 –0.3 (–5 to 4) 0.87
FEV1/FVC 0.52 ± 0.13 0.51 ± 0.13 0.01 (–0.02 to 0.03) 0.64
Current smoker 291 (31%) 48 (51%) <0.001
Pack-years 53 ± 24 50 ± 21 3 (–2 to 7) 0.28
Chronic bronchitis 235 (26%) 34 (39%) 0.012
WBC, 1 × 109 cell/ml 7.0 ± 2.0 9.2 ± 2.7 –2.2 (–2.7 to –1.6) <0.001
Serum neutrophil % 61.5 ± 9.9 67.5 ± 8.2 –5.9 (–8.0 to –3.9) <0.001
Serum eosinophil % 3.1 ± 2.2 2.2 ± 1.5 0.9 (0.6–1.3) <0.001
Any AECOPD within previous 
12 months
271 (28.3%) 30 (31.6%) 0.50
TIMP-1, ng/ml 88.5 ± 27.3 99.4 ± 28.5 –10.9 (–16.7 to –5.14) <0.001
Data represented as mean ± SD or n (%). Unpaired t tests used for analyzing differences in continuous variables and χ2 tests used for categorical variables. BD, 
bronchodilator; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; AECOPD, acute exacerbation of COPD; MMP-9, matrix metalloprotease 9.
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elevated MMP-9 (13%–16% absolute difference) as a single biomarker. As these panels of  nonspecific 
biomarker elevations aid in defining an inflammatory phenotype, elevated MMP-9 alone identified a dis-
tinct COPD endotype characterized by current smokers with chronic bronchitis and evidence of  increased 
systemic inflammation, exacerbation risk, and shorter time-to-first event. Unlike the analytes included in 
the panels mentioned above, MMP-9 may be a more biologically relevant marker, given its close relation-
ship with the pathophysiology of  COPD, including tissue degradation, release of  matrikines, and its role 
in inflammation. Further, these observations of  MMP-9’s relation to AECOPD highlight the potential of  
examining other proteases (such as other MMPs and serine proteases; refs. 25, 26) as rational biomarkers 
for studies in large COPD cohorts. One may even envision a panel of  proteases and antiproteases that 
may further delineate risk in a population for loss of  lung function and/or symptom progression.
We found that elevated MMP-9 was present in a modest proportion of  the overall COPD popula-
tion. This observation was not surprising, given the heterogeneity of  COPD, and supports the notion 
that precision-based approaches to managing COPD are of  paramount importance. Placing this into 
context, COPD affects approximately 15 million patients in the US (27). Logically, one could estimate 
that between 1.3 and 4.3 million individuals in the US may have elevated MMP-9 and, thus, may be at 
increased risk for AECOPD and healthcare utilization. It is worth noting that MMP-9 elevations were 
predictive of  exacerbation frequency in both groups, despite differences in overall exacerbation rates 
and severity of  lung function impairment within the individual cohorts and in models adjusted for FEV1 
percent predicted. Further, there was not a dose-dependent relationship between MMP-9 levels and 
GOLD stages, suggesting that MMP-9 does not reflect the degree of  airflow limitation associated with 
disease severity. Hence, the information provided by MMP-9 may have a role in risk stratification in the 
general COPD population — findings that warrant validation.
There are several important limitations to consider for this study. First, although the populations of  both 
cohorts are largely similar, there are some notable differences between cohorts, including lung function, smok-
ing status, and MMP-9 values. We believe these differences may be due to population differences or batch 
effects. For example, participants at all SPIROMICS study sites had MMP-9 values, including representation 
from Black and White races. Of these, a lower proportion of  Black subjects were in the elevated MMP-9 
group compared with the nonelevated MMP-9 group, as shown in Table 2, though this was not statistically 
significant. Conversely, all participants from the COPDGene cohort were exclusively White, somewhat lim-
iting the generalizability from COPDGene alone. Additionally, the Myriad-RBM assays were measured in 2 
Table 3. Differences in characteristics between elevated and nonelevated MMP-9 in COPD in COPDGene
Nonelevated MMP-9 (n = 99) Elevated MMP-9 (n = 41) Mean difference (95% CI) P value
Age, years 65 ± 8 61 ± 10 3.2 (0.05–6.4) 0.045
White 99 (100%) 41 (100%) n/a
Male 74 (48%) 17 (41%) 0.52
BMI, kg/m2 28.0 ± 6.0 27.0 ± 5.3 1.0 (–1.1 to 3.2) 0.35
Post-BD FEV1, % predicted 41 ± 16 43 ± 18 –2 (–8 to 4) 0.51
Post-BD FVC, % predicted 77 ± 18 77 ± 27 –1 (–10 to 9) 0.91
FEV1/FVC 0.40 ± 0.12 0.43 ± 0.13 –0.03 (–0.07 to 0.02) 0.28
Current smoker 13 (13%) 13 (32%) 0.010
Pack-years 55 ± 31 51 ± 23 4 (–6 to 13) 0.42
Chronic bronchitis 21 (21%) 13 (32%) 0.55
WBC, 1 × 109 cell/ml 7.1 ± 1.9 8.8 ± 2.4 –1.7 (–2.4 to –0.9) <0.001
Serum neutrophil % 63 ± 10 67 ± 10 –5 (–8 to –1) 0.009
Serum eosinophil % 3 ± 2 2 ± 2 1 (0–1) 0.075
Any AECOPD within previous 
12 months
50 (50.5%) 26 (63.4%) 0.16
TIMP-1, ng/ml 68.7 ± 14.7 65.8 ± 10.3 2.9 (–2.1 to 7.9) 0.19
Data represented as mean ± SD or n (%). Unpaired t tests used for analyzing differences in continuous variables, and χ2 tests used for categorical 
variables. BD, bronchodilator; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; AECOPD, acute exacerbation of COPD; MMP-9, matrix 
metalloprotease 9.
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batches in SPIROMICS and in 1 batch in COPDGene, potentially adding variability. We did adjust analyses 
for batch to account for these potential differences. Despite these differences, it is intriguing that the use of  a 
threshold level to define elevated MMP-9 performed well in both cohorts. This approach of  using an extreme 
MMP-9 value, as opposed to an unbiased approach examining multiple biomarkers that require adjustment 
for multiple comparisons (4), provides unique information and may be practical in implementing in future 
studies. Additionally, our results were based on a single time-point measure of  MMP-9 in both cohorts, and 
there is a lack of  understanding of  the stability of  the elevated MMP-9 phenotype. However, our analysis of  
the participants in SPIROMICS with follow-up MMP-9 measurements shown in Supplemental Figure 1 sug-
gests that MMP-9 elevation may persist over time and, thus, may be a reliable biomarker for AECOPD risk. 
Finally, these analyses rely on circulating MMP-9 levels in the blood. While this has obvious advantages as 
utilization in clinical practice, future studies should also focus on concomitant measurements of  both MMP-9 
levels and activity in both airway secretions (i.e., sputum or BAL) and blood to inform our understanding of  
MMP-9 in local versus systemic compartments in COPD.
In conclusion, this study provides evidence that MMP-9 elevation is associated with distinct clinical 
features and increased risk for COPD exacerbations, and it may aid in risk prediction. In addition to its 
potential role as a blood-based prognostic biomarker for COPD, MMP-9 elevation may also serve as a preci-
sion medicine–based therapeutic target as novel interventions directed at MMP-9 modulation are developed.
Figure 4. Associations between elevated MMP-9 prospective exacerbations. Models were adjusted for age, race, sex, FEV1 percent predicted, smoking 
status, chronic bronchitis, leukocyte count, and history of previous exacerbations. (A) Logistic regression was used to measure associations with ≥1 AECOPD, 
and (B) Poisson regression was used for exacerbation frequency. Boxes represent the point estimates (OR or IRR), and the horizontal bars represent the 95% 
CI. AECOPD, acute exacerbation of chronic obstructive pulmonary disease; MMP, matrix metalloprotease; OR, odds ratio; IRR, incidence rate ratio.
Figure 5. Kaplan-Meier plots for the probability of remaining free of AECOPD. (A) In SPIROMICS, the median time-to-first event was 10 months shorter in 
individuals with elevated MMP-9 compared with those without MMP-9 elevation (21.7 months [95% CI, 17.5–25.9] versus 31.7 months [95% CI, 27.2–36.2], 
P = 0.015). (B) In COPDGene, the median time-to-first AECOPD was also shorter among the elevated MMP-9 group (14 months [95% CI, 9.4–18.6] versus 21 
months [95% CI, 15–27], P = 0.065). AECOPD, acute exacerbation of chronic obstructive pulmonary disease; MMP, matrix metalloprotease. 
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Methods
Study populations. The SPIROMICS is a multicenter prospective observational study aimed at subclas-
sifying COPD participants into groups through identification of  biomarkers and phenotypes that can 
be used as intermediate outcomes to reliably predict clinical benefit in future clinical trials (Clinical-
Trials.gov, NCT01969344) (28). SPIROMICS enrolled 2,982 individuals between November 2011 and 
January 2015. Participants were categorized into 4 distinct strata: Strata 1, never smokers; Strata 2, 
current and former smokers without airflow obstruction; and Stratas 3–4, which comprised current 
and former smokers with COPD, defined as a postbronchodilator FEV1/forced vital capacity (FVC) 
< 0.70. Participants in Strata 3 had an FEV1 > 50% and Strata 4 had an FEV1 < 50% predicted (29). 
Participants underwent baseline and annual in-person follow-up visits plus quarterly telephone calls. 
We used SPIROMICS participants in Stratas 1 and 2 (non-COPD) to define elevated MMP-9, and par-
ticipants in Stratas 3 and 4 (COPD) were used for analysis of  COPD exacerbations. Data reported here 
include results from the SPIROMICS Core3 dataset (n = 2,954 subjects). For these studies, we report 
data from subjects with COPD, complete clinical information, MMP-9 measurements, WBC count, 
and appropriate longitudinal follow-up AECOPD ascertainment.
As a replication cohort, we used the COPDGene study (ClinicalTrials.gov, NCT00608764; ref. 30). 
Participants with COPD, MMP-9 and WBC count measurements, and prospective AECOPD information 
were included in the analysis. These participants were followed longitudinally at 6-month intervals via an 
automated telephony system, via web-based survey, or by telephone contact (31).
Plasma MMP-9 measurement. Plasma was collected from participants in both studies at baseline. MMP-9 
and TIMP-1 were measured using a commercially available Myriad-RBM multiplex assay in SPIROMICS 
(32) and via a custom Myriad-RBM multiplex assay in COPDGene. MMP-9 values were log-transformed 
to fit a normal distribution. We defined elevated MMP-9 a priori by plasma MMP-9 >95th percentile 
(MMP-9 >2.67 ng/ml, log transformed) as measured in non-COPD SPIROMICS participants. For SPI-
ROMICS, MMP-9 was measured in 2 separate batches due to sample availability (batch 1 was run in May 
2013, and batch 2 was run in February 2014). A subset of  participants in SPIROMCIS had plasma MMP-9 
measured at a subsequent visit that occurred 1 year after the baseline visit.
Phenotypic measurements. Demographics included age, White or Black race, and sex; comorbidities 
were self-reported; smoking status was defined as current or former; and smoking history was reported 
in pack-years. Chronic bronchitis was defined by chronic cough and phlegm definitions (33). Pulmo-
nary function testing was performed according to American Thoracic Society/ European Respirato-
ry Society (ATS/ERS) criteria (29); postbronchodilator spirometry was recorded using a KoKo spi-
rometer in SPIROMICS and an ndd EasyOne spirometer in COPDGene. Participants were stratified 
according to GOLD stage (34).
COPD exacerbation assessment. In both cohorts, AECOPD were self-reported and defined as a worsening 
of  respiratory symptoms lasting longer than 48 hours that warranted treatment with antibiotics and/or 
systemic corticosteroids, irrespective of  treatment location (35).
Statistics. Descriptive statistics, including means and SDs for continuous data and frequencies and 
percentages for categorical data, were calculated for all study variables of  interest. Bivariate analyses 
were conducted by using the unpaired t test or Wilcoxon rank-sum test for continuous variables and the 
χ2 test for categorical variables. ANOVA was used to compare logMMP-9 values across GOLD stages. 
Logistic regression models were used to identify associations with having ≥1 AECOPD during follow-up. 
The frequency of  prospective AECOPD followed a Poisson distribution in both cohorts (Supplemental 
Figure 2); thus, Poisson regression models were used to measure associations with AECOPD frequency 
by calculating IRR and their corresponding 95% CIs.
Variables that were known to have relevance with AECOPD risk; plus, variables statistically significant in 
univariate analyses were included in the multivariable logistic regression and Poisson models, with the same 
set of  variables being included in all multivariable analyses. Variables in the final adjusted logistic and Poisson 
regression models included age, sex, race, postbronchodilator FEV1 percent predicted, current smoking status, 
chronic bronchitis, WBC count, having ≥1 prior exacerbation in the previous year, and elevated MMP-9, as 
well as the batch analysis (in SPIROMICS only). An interaction term was added to the multivariable models 
for both study cohorts in order to determine whether there was a statistically meaningful interaction between 
MMP-9 and WBC count. Pearson’s correlation analyses were performed to assess the correlation between 
the log-transformed MMP-9 values and the frequency of  exacerbations for both study cohorts. Kaplan-Meier 
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survival analysis was used to identify time-to-first AECOPD based on the presence or absence of  elevated 
MMP-9. All statistical tests were 2-sided and were performed using a significance level of  P < 0.05. Statistical 
analyses were conducted using SAS software (version 9.4; SAS Institute).
Study approval. The study protocols for SPIROMICS and COPDGene were approved by the IRBs at all 
participating sites. All participants in both studies provided written informed consent prior to inclusion in 
the respective study.
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